Emergent BioSolutions | EBS - Ação





Ação Alterar Data
Acadia Pharmaceuticals USD 31.57M 3.1M 2026-03
Akebia Therapeutics USD 13M 2.61M 2026-03
ALKERMES USD 336.7M 140.08M 2026-03
Alnylam Pharmaceuticals USD 200.15M 117.43M 2026-03
Amarin USD 183.58M 12.32M 2026-03
ANI Pharmaceuticals USD 143.47M 401K 2026-03
BioMarin Pharmaceutical USD 1.27B 25.66M 2026-03
Coherus Biosciences USD 3.17M 1.12M 2025-12
Emergent BioSolutions USD 328.9M 25.2M 2023-12
Exelixis USD 26.6M 4.92M 2026-03
Glaxosmithkline GBP 6.12B 46M 2025-09
Heron Therapeutics USD 54.57M 2.33M 2022-12
Ionis Pharmaceuticals USD 5.56M 4.49M 2026-03
Lexicon Pharmaceuticals USD 276K 5K 2026-03
Lonza CHF 1.68B 163M 2025-12
Merck USD 6.48B 179M 2026-03
Moderna USD 146M 7M 2026-03
Myriad Genetics USD 27.9M 2.7M 2026-03
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Neurocrine Biosciences USD 64.5M 4.5M 2026-03
Pacira USD 150.37M 2.49M 2026-03
Pfizer USD 10.67B 13M 2026-03
PTC Therapeutics USD 75.57M 4.08M 2026-03
Sanofi EUR 22.69B 1.81B 2025-12
Sarepta Therapeutics USD 1B 86.37M 2026-03
United Therapeutics USD 178.3M 4.8M 2026-03
Vanda Pharmaceuticals USD 1.85M 190K 2025-12